HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.

AbstractBACKGROUND:
Previous studies have suggested that the acid secretory capacity of the Chinese population is lower than that of the Western population.
AIM:
To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease.
METHODS:
Forty-four patients (male to female ratio, 27 : 17; mean age, 53 years; 55% with oesophagitis) with gastro-oesophageal reflux disease were randomized to receive lansoprazole 30 mg or 15 mg once daily for 4 weeks. Measurement of the 24-h oesophageal and intragastric pH, gastro-oesophageal reflux disease symptoms and quality of life was performed at baseline and during the last week of each dosing period.
RESULTS:
Lansoprazole 30 mg maintained an intragastric pH > 4 for 10.5 h vs. 9.6 h for lansoprazole 15 mg (P = 0.44). The percentage total time at oesophageal pH < 4 was similar for lansoprazole 30 mg and 15 mg (2.0% vs. 2.3%, P = 0.30). The proportion of patients with complete cure of heartburn and acid regurgitation and the quality of life assessment were similar for lansoprazole 30 mg and 15 mg. Both dosages of lansoprazole were well tolerated and the compliance was 100% in both groups.
CONCLUSION:
Lansoprazole dosages of 30 mg and 15 mg once daily provide a satisfactory decrease for oesophageal acid exposure and are equally effective for the treatment of gastro-oesophageal reflux disease in the Chinese population.
AuthorsW M Wong, K C Lai, W M Hui, K F Lam, J Q Huang, W H C Hu, N Y H Wong, C L K Lam, H H X Xia, A O O Chan, S K Lam, B C Y Wong
JournalAlimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 19 Issue 4 Pg. 455-62 (Feb 15 2004) ISSN: 0269-2813 [Print] England
PMID14871286 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Lansoprazole
  • Omeprazole
Topics
  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents (administration & dosage)
  • China (ethnology)
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Gastric Acidity Determination
  • Gastroesophageal Reflux (drug therapy, ethnology)
  • Humans
  • Hydrogen-Ion Concentration
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole (administration & dosage, analogs & derivatives)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: